Perampanel and levetiracetam both control SeLECTS with minor sleep differences

This small pilot cohort offers preliminary, exploratory comparative data on how two anti-seizure medications differ in objective sleep architecture in children with self-limited epilepsy with centrotemporal spikes.

perampanellevetiracetamAMPA receptor antagonistanti-seizure medicationSeLECTSself-limited epilepsy with centrotemporal spikespediatric epilepsysleep architecturepolysomnographycohort studyneurology Neurology / Neuropharmacology

Background Information

PER may enhance sleep in children with SeLECTS.

Self-limited epilepsy with centrotemporal spikes (SeLECTS) often affects sleep, impacting overall management in children. Both levetiracetam (LEV) and perampanel (PER) showed effective seizure control; PER may improve sleep architecture, reducing light sleep and awakenings. While both treatments are viable, PER may offer additional sleep benefits. Longer studies are needed for conclusive evidence. LEV and PER effectively control seizures in SeLECTS; PER shows potential sleep benefits.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Yan L, Xie L, Li T, Chen J, Jiang L

Citation: Yan L, Xie L, Li T, et al. Efficacy and sleep impact of perampanel versus levetiracetam monotherapy for SeLECTS: A pilot prospective cohort study. Epilepsy & behavior : E&B. 2026;184:111228. doi:10.1016/j.yebeh.2026.111228

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →